Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Recent Registrations
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
January
-
February
-
March
-
April
-
May
- June -
July
-
August
-
September
-
Oktober
-
November
-
December
|
2002
-
2003
-
2004
-
2005
-
2006
-
2007
-
2008
-
2009
-
2010
-
2011
-
2012
-
2013
-
2014
-
2015
-
2016
-
2017
-
2018
-
2019
-
2020
-
2021
- 2022 -
2023
-
2024
-
2025
June 2022 - 62 products
L
IP
CI
Yuflyma 80 mg
0.8 ml
646.09
720.90
10 %
Injection solution in prefilled syringe: Adalimumabum 80mg / 0.8ml
iQone Healthcare
Switzerland SA
B / SL
FB
G
L
IP
CI
Yuflyma 80 mg
0.8 ml
646.09
720.90
10 %
solution injectable en seringue préremplie avec protège-aiguille: Adalimumabum 80mg / 0.8ml
iQone Healthcare
Switzerland SA
B / SL
FB
G
L
IP
Co-Amoxicillin Labatec 2,2 g
i.v.
10
33.94
53.35
10 %
Dry substance: 2 Active Agents
Labatec Pharma SA
A / SL / SG
FB
G
IP
CI
Fesoterodin-Mepha 4 mg
14
9.02
26.25
10 %
Delayed release tablets: Fesoterodini Fumaras 4 mg
Mepha Pharma AG
B / SL / SG
FB
G
IP
CI
Fesoterodin-Mepha 4 mg
84
52.66
73.70
10 %
Delayed release tablets: Fesoterodini Fumaras 4 mg
Mepha Pharma AG
B / SL / SG
FB
G
IP
Fesoterodin-Mepha 8 mg
14
9.45
26.70
10 %
Delayed release tablets: Fesoterodini Fumaras 8 mg
Mepha Pharma AG
B / SL / SG
FB
G
IP
Fesoterodin-Mepha 8 mg
84
55.38
76.65
10 %
Delayed release tablets: Fesoterodini Fumaras 8 mg
Mepha Pharma AG
B / SL / SG
FB
G
IP
CI
Olmesartan-Mepha Teva 10 mg
28
11.07
28.45
10 %
Coated tablets: Olmesartanum Medoxomilum 10 mg
Mepha Pharma AG
B / SL / SG
FB
G
IP
CI
Olmesartan-Mepha Teva 10 mg
98
32.95
52.25
10 %
Coated tablets: Olmesartanum Medoxomilum 10 mg
Mepha Pharma AG
B / SL / SG
FB
G
IP
Olmesartan-Mepha Teva 20 mg
28
13.30
30.90
10 %
Coated tablets: Olmesartanum Medoxomilum 20 mg
Mepha Pharma AG
B / SL / SG
FB
G
IP
Olmesartan-Mepha Teva 20 mg
98
39.55
59.45
10 %
Coated tablets: Olmesartanum Medoxomilum 20 mg
Mepha Pharma AG
B / SL / SG
FB
G
IP
Olmesartan-Mepha Teva 40 mg
28
16.97
34.90
10 %
Coated tablets: Olmesartanum Medoxomilum 40 mg
Mepha Pharma AG
B / SL / SG
FB
G
IP
Olmesartan-Mepha Teva 40 mg
98
50.46
71.30
10 %
Coated tablets: Olmesartanum Medoxomilum 40 mg
Mepha Pharma AG
B / SL / SG
FB
G
L
IP
Caspofungin Labatec 50 mg
264.53
304.75
10 %
Poudre pour solution à diluer pour perfusion: Caspofunginum 50 mg
Labatec Pharma SA
A / SL / SG
FB
G
L
IP
Caspofungin Labatec 70 mg
336.30
383.00
10 %
Poudre pour solution à diluer pour perfusion: Caspofunginum 70 mg
Labatec Pharma SA
●
A / SL / SG
FB
G
L
IP
Co-Amoxicillin Labatec 1,2 g
i.v.
10
21.93
40.25
10 %
poudre pour solution pour injection/perfusion: 2 Active Agents
Labatec Pharma SA
A / SL / SG
FB
G
L
IP
CI
Tezspire
1036.42
1143.60
10 %
Injection solution in prefilled syringe: Tezepelumabum 210 mg
AstraZeneca AG
B / SL
FB
G
L
IP
CI
Yuflyma 40 mg
0.4 ml
371.10
419.95
10 %
Injection solution in prefilled syringe: Adalimumabum 40mg / 0.4ml
iQone Healthcare
Switzerland SA
B / SL
FB
G
L
IP
CI
Yuflyma 40 mg
2 x 0.4 ml
742.20
823.50
10 %
Injection solution in prefilled syringe: Adalimumabum 40mg / 0.4ml
iQone Healthcare
Switzerland SA
B / SL
FB
G
L
IP
CI
Paxlovid
30
958.62
1058.95
10 %
Coated tablets: Ritonavirum 100 mg
Coated tablets: Nirmatrelvirum 150 mg
Pfizer AG
A / SL
FB
G
L
IP
CI
Scemblix 20 mg
60
2130.99
2334.00
10 %
Coated tablets: Asciminibum 20 mg
Novartis Pharma
Schweiz AG
A / SL
FB
G
L
IP
Scemblix 40 mg
60
4261.98
4651.55
10 %
Coated tablets: Asciminibum 40 mg
Novartis Pharma
Schweiz AG
A / SL
FB
G
L
IP
CI
Orladeyo 150 mg
28
12756.64
13396.10
10 %
Capsules: Berotralstatum 150 mg
BioCryst Schweiz GmbH
B / SL
FB
G
L
IP
Remicade 100 mg
468.27
526.50
10 %
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Infliximabum 100 mg
APS-Arzneimittel-
Parallelimport-
Service AG
A / SL
FB
G
L
IP
Remsima 100 mg
452.29
510.10
10 %
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Infliximabum 100 mg
APS-Arzneimittel-
Parallelimport-
Service AG
A / SL
FB
G
L
IP
CI
Yuflyma 40 mg
0.4 ml
371.10
419.95
10 %
solution injectable en seringue préremplie avec protège-aiguille: Adalimumabum 40mg / 0.4ml
iQone Healthcare
Switzerland SA
B / SL
FB
G
L
IP
CI
Yuflyma 40 mg
2 x 0.4 ml
742.20
823.50
10 %
solution injectable en seringue préremplie avec protège-aiguille: Adalimumabum 40mg / 0.4ml
iQone Healthcare
Switzerland SA
B / SL
FB
G
IP
CI
Yuflyma 40 mg
2 x 0.4 ml
742.20
869.30
k.A.
Injection solution in prefilled syringe: Adalimumabum 40mg / 0.4ml
iQone Healthcare
Switzerland SA
B
FB
G
CI
CM
DROPA Bronchialpastillen
neue Formel
40
PR
PR
k.A.
Pastilles: 6 Active Agents
DR. BÄHLER DROPA AG
E
FB
G
IP
CI
Amlodipin Valsartan HCT
Viatris 5 mg/160 mg/12.5 mg
28
15.58
33.35
k.A.
Coated tablets: 3 Active Agents
Viatris Pharma GmbH
B
FB
G
IP
CI
Amlodipin Valsartan HCT
Viatris 5 mg/160 mg/12.5 mg
98
54.45
75.65
k.A.
Coated tablets: 3 Active Agents
Viatris Pharma GmbH
B
FB
G
IP
CI
Amlodipin Valsartan HCT
Viatris 10 mg/160 mg/12.5 mg
28
15.58
33.35
k.A.
Coated tablets: 3 Active Agents
Viatris Pharma GmbH
B
FB
G
IP
CI
Amlodipin Valsartan HCT
Viatris 10 mg/160 mg/12.5 mg
98
54.45
75.65
k.A.
Coated tablets: 3 Active Agents
Viatris Pharma GmbH
B
FB
G
IP
CI
Amlodipin Valsartan HCT
Viatris 5 mg/160 mg/25 mg
28
15.58
33.35
k.A.
Coated tablets: 3 Active Agents
Viatris Pharma GmbH
B
FB
G
IP
CI
Amlodipin Valsartan HCT
Viatris 5 mg/160 mg/25 mg
98
54.45
75.65
k.A.
Coated tablets: 3 Active Agents
Viatris Pharma GmbH
B
FB
G
IP
CI
Amlodipin Valsartan HCT
Viatris 10 mg/160 mg/25 mg
28
15.58
33.35
k.A.
Coated tablets: 3 Active Agents
Viatris Pharma GmbH
B
FB
G
IP
CI
Amlodipin Valsartan HCT
Viatris 10 mg/160 mg/25 mg
98
54.45
75.65
k.A.
Coated tablets: 3 Active Agents
Viatris Pharma GmbH
B
FB
G
IP
CI
Anouk 0.075 mg
28
PR
PR
k.A.
Coated tablets: Desogestrelum
Spirig HealthCare AG
B
FB
G
IP
CI
Anouk 0.075 mg
3 x 28
PR
PR
k.A.
Coated tablets: Desogestrelum
Spirig HealthCare AG
B
FB
G
IP
CI
Anouk 0.075 mg
6 x 28
PR
PR
k.A.
Coated tablets: Desogestrelum
Spirig HealthCare AG
B
FB
G
Sitagliptin-Metformin
Xiromed 50 mg/ 500 mg
56
PR
PR
k.A.
Coated tablets: 2 Active Agents
Xiromed SA
B
FB
G
Sitagliptin-Metformin
Xiromed 50 mg/ 500 mg
196
PR
PR
k.A.
Coated tablets: 2 Active Agents
Xiromed SA
B
FB
G
Sitagliptin-Metformin
Xiromed 50 mg/ 850 mg
56
PR
PR
k.A.
Coated tablets: 2 Active Agents
Xiromed SA
B
FB
G
Sitagliptin-Metformin
Xiromed 50 mg/ 850 mg
196
PR
PR
k.A.
Coated tablets: 2 Active Agents
Xiromed SA
B
FB
G
Sitagliptin-Metformin
Xiromed 50 mg/1000 mg
56
PR
PR
k.A.
Coated tablets: 2 Active Agents
Xiromed SA
B
FB
G
Sitagliptin-Metformin
Xiromed 50 mg/1000 mg
196
PR
PR
k.A.
Coated tablets: 2 Active Agents
Xiromed SA
B
FB
G
IP
CI
Nitisinon NOBEL 5 mg
60
PR
PR
k.A.
Capsules: Nitisinonum 5 mg
NOBEL Pharma Schweiz AG
B
FB
G
IP
Nitisinon NOBEL 10 mg
60
PR
PR
k.A.
Capsules: Nitisinonum 10 mg
NOBEL Pharma Schweiz AG
B
FB
G
IP
Nitisinon NOBEL 20 mg
60
PR
PR
k.A.
Capsules: Nitisinonum 20 mg
NOBEL Pharma Schweiz AG
B
FB
G
Subutex 100 mg
PR
PR
k.A.
Depot-Injektionslösung: Buprenorphinum 100mg / 0.5ml
Indivior Schweiz AG
A+
FB
G
Subutex 300 mg
PR
PR
k.A.
Depot-Injektionslösung: Buprenorphinum 300mg / 1.5ml
Indivior Schweiz AG
A+
FB
G
IP
Remicade 100 mg
PR
PR
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Infliximabum 100 mg
APS-Arzneimittel-
Parallelimport-
Service AG
A
FB
G
IP
Remicade 100 mg
PR
PR
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Infliximabum 100 mg
APS-Arzneimittel-
Parallelimport-
Service AG
A
FB
G
IP
Remsima 100 mg
PR
PR
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Infliximabum 100 mg
APS-Arzneimittel-
Parallelimport-
Service AG
A
FB
G
IP
Remsima 100 mg
PR
PR
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Infliximabum 100 mg
APS-Arzneimittel-
Parallelimport-
Service AG
A
FB
G
IP
CI
CM
Amavita Flumol Grippe
12
PR
PR
k.A.
Pulver zur Herstellung einer Lösung zum Einnehmen: 4 Active Agents
Amavita Health Care AG
D
FB
G
IP
CI
CM
Coop Vitality Flumol
Grippe
12
PR
PR
k.A.
Pulver zur Herstellung einer Lösung zum Einnehmen: 4 Active Agents
Coop Vitality Health
Care GmbH
D
FB
G
IP
CI
CM
SUN STORE Flumol Grippe
12
PR
PR
k.A.
Pulver zur Herstellung einer Lösung zum Einnehmen: 4 Active Agents
Sun Store Health Care AG
D
FB
G
IP
CI
Nitisinon NOBEL 4 mg/ml
100 ml
PR
PR
k.A.
Suspension: Nitisinonum 4 mg/ml
NOBEL Pharma Schweiz AG
B
FB
G
IP
CI
Yuflyma 40 mg
2 x 0.4 ml
742.20
869.30
k.A.
solution injectable en seringue préremplie avec protège-aiguille: Adalimumabum 40mg / 0.4ml
iQone Healthcare
Switzerland SA
B
FB
G
IP
CI
Voltaren Dolo Patch 140 mg
5
PR
PR
k.A.
wirkstoffhaltiges Pflaster: Diclofenacum Natricum 140 mg
Haleon Schweiz AG
D
FB
G
IP
CI
Voltaren Dolo Patch 140 mg
10
PR
PR
k.A.
wirkstoffhaltiges Pflaster: Diclofenacum Natricum 140 mg
Haleon Schweiz AG
D
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2025
©ywesee GmbH
Settings
|
Help
|
FAQ
|
Login
|
Contact
|
Home
